Compare OWLS & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLS | LRMR |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Taiwan | United States |
| Employees | 75 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.4M | 455.8M |
| IPO Year | N/A | 2014 |
| Metric | OWLS | LRMR |
|---|---|---|
| Price | $5.37 | $3.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $11.00 | ★ $16.50 |
| AVG Volume (30 Days) | 19.6K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $375.69 | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.10 | $2.72 |
| 52 Week High | $29.00 | $6.42 |
| Indicator | OWLS | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 46.80 |
| Support Level | $5.24 | $3.01 |
| Resistance Level | $6.14 | $3.77 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 34.85 | 12.10 |
OBOOK Holdings Inc operate as a blockchain-powered technology company. It provides solutions across three main business segments: payments, hospitality, and e-commerce, serving businesses and individuals whose commercial activities involve cross-border transactions. The company has five reportable segments: Payment service provides payment solutions to customers, including payment gateway services and payout services; Hospitality-related software services provide the subscription to the OwlNest PMS and the add-on room fee collection services offered to the clients using OwlNest; Hospitality-related platform services that provide an OTA platform and offline platform services offering accommodation services; The E-commerce platform engages in selling products online; and Other services.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.